NASDAQ:BBIO - BridgeBio Pharma Stock Price, News & Analysis

-0.02 (-0.07 %)
(As of 08/22/2019 10:36 AM ET)
Today's Range
Now: $29.80
50-Day Range
MA: $27.94
52-Week Range
Now: $29.80
Volume200 shs
Average Volume157,964 shs
Market Capitalization$3.48 billion
P/E RatioN/A
Dividend YieldN/A
BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company was founded in 2015 and is headquartered in Palo Alto, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BBIO



Sales & Book Value

Annual SalesN/A



Market Cap$3.48 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive BBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.

BridgeBio Pharma (NASDAQ:BBIO) Frequently Asked Questions

What is BridgeBio Pharma's stock symbol?

BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO."

What price target have analysts set for BBIO?

8 analysts have issued 1 year price targets for BridgeBio Pharma's stock. Their predictions range from $34.00 to $50.00. On average, they expect BridgeBio Pharma's share price to reach $40.1250 in the next twelve months. This suggests a possible upside of 34.4% from the stock's current price. View Analyst Price Targets for BridgeBio Pharma.

What is the consensus analysts' recommendation for BridgeBio Pharma?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BridgeBio Pharma.

Has BridgeBio Pharma been receiving favorable news coverage?

Media stories about BBIO stock have trended positive recently, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BridgeBio Pharma earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for BridgeBio Pharma.

Who are some of BridgeBio Pharma's key competitors?

What other stocks do shareholders of BridgeBio Pharma own?

Who are BridgeBio Pharma's key executives?

BridgeBio Pharma's management team includes the folowing people:
  • Dr. Neil Kumar, Co-Founder, CEO & Director (Age 40)
  • Dr. Brian C. Stephenson, Chief Financial Officer (Age 38)
  • Dr. Uma Sinha, Chief Scientific Officer (Age 62)
  • Dr. Cameron Turtle, Sr. VP of Portfolio Management & Corp. Devel. (Age 29)
  • Dr. Charles J. Homcy, Chairman of Pharmaceuticals & Director (Age 71)

When did BridgeBio Pharma IPO?

(BBIO) raised $225 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

When did BridgeBio Pharma's quiet period expire?

BridgeBio Pharma's quiet period expired on Tuesday, August 6th. BridgeBio Pharma had issued 20,500,000 shares in its initial public offering on June 27th. The total size of the offering was $348,500,000 based on an initial share price of $17.00. During BridgeBio Pharma's quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are BridgeBio Pharma's major shareholders?

BridgeBio Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Kohlberg Kravis Roberts & Co. L.P. (30.62%), Viking Global Investors LP (22.09%), Perceptive Advisors LLC (5.57%), Aisling Capital Management LP (3.18%), Cormorant Asset Management LP (2.31%) and Hillhouse Capital Advisors LTD. (1.95%). Company insiders that own BridgeBio Pharma stock include Brian C Stephenson, Genetic Disorder LP Kkr and Global Investors Lp Viking. View Institutional Ownership Trends for BridgeBio Pharma.

Which major investors are buying BridgeBio Pharma stock?

BBIO stock was bought by a variety of institutional investors in the last quarter, including Kohlberg Kravis Roberts & Co. L.P., Viking Global Investors LP, Perceptive Advisors LLC, Aisling Capital Management LP, Cormorant Asset Management LP, Hillhouse Capital Advisors LTD., Hillhouse Capital Management LTD. and JPMorgan Chase & Co.. Company insiders that have bought BridgeBio Pharma stock in the last two years include Brian C Stephenson, Genetic Disorder LP Kkr and Global Investors Lp Viking. View Insider Buying and Selling for BridgeBio Pharma.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BridgeBio Pharma's stock price today?

One share of BBIO stock can currently be purchased for approximately $29.8514.

How big of a company is BridgeBio Pharma?

BridgeBio Pharma has a market capitalization of $3.49 billion. BridgeBio Pharma employs 152 workers across the globe.View Additional Information About BridgeBio Pharma.

What is BridgeBio Pharma's official website?

The official website for BridgeBio Pharma is

How can I contact BridgeBio Pharma?

BridgeBio Pharma's mailing address is 421 KIPLING STREET, PALO ALTO CA, 94301. The company can be reached via phone at 650-391-9740.

MarketBeat Community Rating for BridgeBio Pharma (NASDAQ BBIO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  32 (Thanks for Voting!)
Underperform Votes:  26 (Thanks for Voting!)
Total Votes:  58
MarketBeat's community ratings are surveys of what our community members think about BridgeBio Pharma and other stocks. Vote "Outperform" if you believe BBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/22/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel